Endocrine / Somatostatin Analog Research Peptides Guide
Overview
This guide covers 4 research peptides in the Endocrine / Somatostatin Analog category. Each compound is evaluated on its evidence base, mechanism, safety profile, and current clinical status.
Octreotide — FDA Approved
Evidence: A | Status: FDA-approved (Sandostatin 1988; Sandostatin LAR 1998)
Octreotide is a synthetic 8-amino-acid cyclic peptide (MW ~1019.2 g/mol) that mimics the pharmacological actions of natural somatostatin but with a significantly longer half-life.
Use cases: Neuroendocrine Tumor Management, Acromegaly, Hormonal Symptom Control
Lanreotide — FDA Approved
Evidence: A | Status: FDA-approved (Somatuline Depot for acromegaly 2007; GEP-NETs 2014)
Lanreotide is a synthetic 8-amino-acid cyclic somatostatin analog (MW ~1096.3 g/mol) available as a long-acting deep subcutaneous depot injection (Somatuline Depot/Autogel).
Use cases: Neuroendocrine Tumor Management, Acromegaly, Hormonal Symptom Control
Pasireotide — FDA Approved
Evidence: A | Status: FDA-approved (Signifor SC for Cushing disease, 2012; Signifor LAR for acromegaly, 2014)
Pasireotide is a synthetic cyclohexapeptide somatostatin analog (MW ~1164.7 g/mol) with a unique broad somatostatin receptor binding profile, exhibiting high affinity for SSTR1, SSTR2, SSTR3, and SSTR5 (40-fold higher SSTR5 affinity than octreotide).
Use cases: Cushing Disease Management, Acromegaly, Neuroendocrine Tumor Management
Somatostatin — Well-Characterized Endogenous Hormone
Evidence: B | Status: Limited clinical use (IV infusion only); synthetic analogs preferred for therapeutic applications
Somatostatin (SST-14) is an endogenous 14-amino-acid cyclic peptide hormone (MW ~1637.9 g/mol) produced in the hypothalamus, pancreatic delta cells, and gastrointestinal tract.
Use cases: Research Reagent, Acute Variceal Bleeding (limited markets), Endocrine Research